Regulus Therapeutics (RGLS) Plans Presentation of New RG-012 at ERA-EDTA Congress
Tweet Send to a Friend
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced that new data on RG-012, the company's anti-miR targeting microRNA-21 for the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
